US digital physical therapy specialist Sword Health has bought its competitor Kaia Health for $285 million, positioning it for expansion in Europe.

The FDA has started a priority review of Otsuka’s triple-acting drug for ADHD, setting up a decision on the first-in-class drug in July.

Tenpoint Therapeutics landed an FDA approval for its presbyopia eye drop on Wednesday, entering a tricky commercial landscape for therapeutic alternatives to reading glasses and

ChenMed CEO Chris Chen said the primary care chain isn’t encouraging the use of GLP-1 drugs for weight loss after finding the medications led to

Drugmakers will likely be able to handle the impacts of the third round of Medicare negotiations, analysts say, even as the biopharma industry continues to